Adecoagro S.A. (AGRO)
Every figure this model derived for AGRO, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2024-12-31.
The figures, and where each came from
This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.
| Figure | Value | XBRL tag | As at |
|---|---|---|---|
| capex | 260,211,000 | PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
2024-12-31 |
| cash | 339,998,000 | CashAndCashEquivalents |
2025-09-30 |
| current assets | 1,361,032,000 | CurrentAssets |
2025-09-30 |
| current liabilities | 486,098,000 | CurrentLiabilities |
2025-09-30 |
| equity | 1,371,989,000 | EquityAttributableToOwnersOfParent |
2025-09-30 |
| interest expense | 40,869,000 | InterestExpense |
2024-12-31 |
| ocf | 328,331,000 | CashFlowsFromUsedInOperatingActivities |
2024-12-31 |
| revenue | 1,518,907,000 | Revenue |
2024-12-31 |
| sbc | 6,680,000 | AdjustmentsForSharebasedPayments |
2024-12-31 |
The ratios
The figures themselves rather than their scores — what somebody looking up AGRO on one particular measure came for.
| Ratio | Value |
|---|---|
| cash operating margin | 24.9 |
| current ratio | 2.8 |
| current ratio reported | 2.8 |
| dilution pct | -4.11 |
| ebit cagr | -0.91 |
| ebit yoy | -24.53 |
| ev ebit | 14.99 |
| ev owner earnings | 44.47 |
| ev sales | 1.8 |
| fcf margin | 4.48 |
| growth cv | 1.32 |
| interest cover | 4.46 |
| net debt ebitda | 3.41 |
| operating margin | 12.0 |
| owner earnings margin | 4.05 |
| revenue growth | 16.94 |
| revenue growth per share | 21.95 |
| roic | 5.46 |
| rule of 40 | 28.94 |
| sbc pct revenue | 0.44 |
Everything else this filing tags
280 more elements from AGRO's own XBRL that this model has no measure for, newest reading each, largest first. Nothing here is converted, added up or renamed — it is the filing's own element names and the filing's own numbers.
| Element | Newest | As of | Periods | Unit |
|---|---|---|---|---|
Assets | 3,645,047,000 | 2025-09-30 | 19 | USD |
EquityAndLiabilities | 3,645,047,000 | 2025-09-30 | 19 | USD |
NoncurrentAssets | 2,284,015,000 | 2025-09-30 | 19 | USD |
Liabilities | 2,208,489,000 | 2025-09-30 | 19 | USD |
NoncurrentLiabilities | 1,722,391,000 | 2025-09-30 | 19 | USD |
PropertyPlantAndEquipment | 1,681,601,000 | 2025-09-30 | 28 | USD |
NetAssetsLiabilities | 1,440,000,000 | 2025-09-30 | 2 | USD |
Equity | 1,436,558,000 | 2025-09-30 | 36 | USD |
RevenueOfCombinedEntity | 1,369,462,000 | 2022-12-31 | 2 | USD |
Borrowings | 1,236,971,000 | 2025-09-30 | 26 | USD |
RiskExposureAssociatedWithInstrumentsSharingCharacteristic | -1,149,301,000 | 2025-09-30 | 17 | USD |
LongtermBorrowings | 1,054,192,000 | 2025-09-30 | 19 | USD |
ExpenseByNature | 917,972,000 | 2025-09-30 | 26 | USD |
CostOfSales | 841,418,000 | 2025-09-30 | 28 | USD |
NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued | 760,136,000 | 2025-09-30 | 18 | USD |
SharePremium | 636,139,000 | 2025-09-30 | 19 | USD |
ProceedsFromNoncurrentBorrowings | 552,622,000 | 2025-09-30 | 26 | USD |
RetainedEarnings | 525,101,000 | 2025-09-30 | 19 | USD |
TradeAndOtherReceivables | 446,053,000 | 2025-09-30 | 18 | USD |
ReserveOfExchangeDifferencesOnTranslation | -424,636,000 | 2025-09-30 | 19 | USD |
Inventories | 407,286,000 | 2025-09-30 | 19 | USD |
RightofuseAssets | 400,871,000 | 2025-09-30 | 23 | USD |
TradeAndOtherCurrentReceivables | 389,085,000 | 2025-09-30 | 19 | USD |
LeaseLiabilities | 368,075,000 | 2025-09-30 | 20 | USD |
DeferredTaxLiabilities | 344,906,000 | 2025-09-30 | 19 | USD |
AdditionsFromSubsequentExpenditureRecognisedAsAssetBiologicalAssets | 341,602,000 | 2025-09-30 | 18 | USD |
DeferredTaxLiabilityAsset | 323,938,000 | 2025-09-30 | 28 | USD |
NoncurrentLeaseLiabilities | 317,869,000 | 2025-09-30 | 14 | USD |
ShorttermDepositsClassifiedAsCashEquivalents | 283,363,000 | 2025-09-30 | 18 | USD |
RevaluationSurplus | 279,150,000 | 2025-09-30 | 17 | USD |
CashFlowsFromUsedInInvestingActivities | -262,529,000 | 2025-09-30 | 26 | USD |
GrossProfit | 255,453,000 | 2025-09-30 | 28 | USD |
CashFlowsFromUsedInFinancingActivities | 252,740,000 | 2025-09-30 | 26 | USD |
BearerPlants | 238,910,000 | 2017-12-31 | 2 | USD |
AdjustmentsForReconcileProfitLoss | 236,116,000 | 2025-09-30 | 26 | USD |
BiologicalAssets | 234,707,000 | 2025-09-30 | 28 | USD |
FinishedGoods | 220,723,000 | 2025-09-30 | 36 | USD |
TradeAndOtherPayables | 211,055,000 | 2025-09-30 | 18 | USD |
TradeAndOtherCurrentPayables | 210,065,000 | 2025-09-30 | 19 | USD |
PropertyPlantAndEquipmentPledgedAsSecurity | 205,100,000 | 2025-09-30 | 18 | USD |
RepaymentsOfNoncurrentBorrowings | 200,271,000 | 2025-09-30 | 26 | USD |
CurrentBiologicalAssets | 193,376,000 | 2025-09-30 | 19 | USD |
RawMaterials | 186,563,000 | 2025-09-30 | 18 | USD |
CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings | 182,779,000 | 2025-09-30 | 19 | USD |
AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment | 180,150,000 | 2025-09-30 | 18 | USD |
TradeAndOtherPayablesUndiscountedCashFlows | 174,863,000 | 2024-12-31 | 16 | USD |
ChangesInBiologicalAssets | 171,278,000 | 2025-09-30 | 26 | USD |
ProceedsFromCurrentBorrowings | 169,901,000 | 2024-12-31 | 16 | USD |
TradeAndOtherCurrentPayablesToTradeSuppliers | 169,036,000 | 2025-09-30 | 18 | USD |
IssuedCapital | 158,072,718 | 2025-11-07 | 23 | USD |
RepaymentsOfCurrentBorrowings | 154,699,000 | 2025-09-30 | 26 | USD |
OtherReserves | 153,237,000 | 2025-09-30 | 17 | USD |
AdjustmentsForDepreciationExpense | 144,232,000 | 2025-09-30 | 26 | USD |
DepreciationPropertyPlantAndEquipment | 144,232,000 | 2025-09-30 | 18 | USD |
CashFlowsFromUsedInOperations | 141,543,000 | 2025-09-30 | 26 | USD |
IncreaseDecreaseInCashAndCashEquivalents | 128,902,000 | 2025-09-30 | 26 | USD |
DepreciationAndAmortisationExpense | 123,475,000 | 2025-09-30 | 26 | USD |
SellingExpense | 111,316,000 | 2025-09-30 | 28 | USD |
EmployeeBenefitsExpense | 106,637,000 | 2025-09-30 | 26 | USD |
CurrentTradeReceivables | 105,382,000 | 2025-09-30 | 18 | USD |
NumberOfSharesIssued | 105,381,815 | 2025-06-06 | 3 | shares |
AdjustmentsForDecreaseIncreaseInInventories | -103,725,000 | 2025-09-30 | 26 | USD |
AdjustedWeightedAverageShares | 103,069,000 | 2024-12-31 | 24 | shares |
WeightedAverageShares | 102,604,000 | 2024-12-31 | 24 | shares |
CashOutflowForLeases | 98,478,000 | 2024-12-31 | 7 | USD |
OtherCashPaymentsToAcquireInterestsInJointVenturesClassifiedAsInvestingActivities | 96,000,000 | 2025-09-30 | 2 | USD |
ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity | 92,340,000 | 2024-12-31 | 24 | USD |
GeneralAndAdministrativeExpense | 90,014,000 | 2025-09-30 | 28 | USD |
PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities | 85,102,000 | 2025-09-30 | 20 | USD |
FinanceCosts | 79,104,000 | 2025-09-30 | 28 | USD |
SecuredBankLoansReceived | 78,413,000 | 2025-09-30 | 18 | USD |
GainsLossesOnFairValueAdjustmentBiologicalAssets | 77,479,000 | 2025-09-30 | 18 | USD |
AdjustmentsForDecreaseIncreaseInTradeAccountReceivable | -75,879,000 | 2025-09-30 | 26 | USD |
NotionalAmount | 72,299,000 | 2020-12-31 | 10 | USD |
AdjustmentsForDecreaseIncreaseInBiologicalAssets | 70,253,000 | 2025-09-30 | 26 | USD |
ProfitLossFromOperatingActivities | 66,186,000 | 2025-09-30 | 28 | USD |
NoncontrollingInterests | 64,569,000 | 2025-09-30 | 19 | USD |
AdjustmentsForFinanceCosts | 64,563,000 | 2025-09-30 | 26 | USD |
CurrentReceivablesFromTaxesOtherThanIncomeTax | 62,236,000 | 2025-09-30 | 18 | USD |
FinanceIncomeCost | -60,097,000 | 2025-09-30 | 28 | USD |
DepreciationRightofuseAssets | 58,847,000 | 2025-09-30 | 20 | USD |
NoncurrentReceivables | 56,968,000 | 2025-09-30 | 19 | USD |
Cash | 56,635,000 | 2025-09-30 | 18 | USD |
IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets | 52,192,000 | 2025-09-30 | 4 | USD |
CurrentLeaseLiabilities | 50,206,000 | 2025-09-30 | 14 | USD |
OtherComprehensiveIncomeNetOfTaxGainsLossesOnRevaluation | 48,437,000 | 2025-09-30 | 25 | USD |
CurrentAdvancesToSuppliers | 46,470,000 | 2025-09-30 | 18 | USD |
InterestPaidClassifiedAsFinancingActivities | 44,930,000 | 2025-09-30 | 26 | USD |
NoncurrentBiologicalAssets | 41,331,000 | 2025-09-30 | 19 | USD |
FinancialAssets | 40,506,000 | 2025-09-30 | 1 | USD |
NoncurrentReceivablesFromTaxesOtherThanIncomeTax | 39,995,000 | 2025-09-30 | 18 | USD |
RepairsAndMaintenanceExpense | 38,605,000 | 2025-09-30 | 26 | USD |
ShorttermEmployeeBenefitsAccruals | 37,582,000 | 2025-09-30 | 19 | USD |
GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss | -37,569,000 | 2024-12-31 | 20 | USD |
IntangibleAssetsAndGoodwill | 35,423,000 | 2025-09-30 | 20 | USD |
DividendsPaid | 35,000,000 | 2025-09-30 | 30 | USD |
IncreaseDecreaseThroughOtherDistributionsToOwners | 35,000,000 | 2022-12-31 | 1 | USD |
DividendPayables | 35,000,000 | 2025-06-17 | 7 | USD |
InvestmentProperty | 34,208,000 | 2025-09-30 | 28 | USD |
AdditionsToRightofuseAssets | 33,680,000 | 2025-09-30 | 13 | USD |
InterestExpenseOnLeaseLiabilities | 33,459,000 | 2025-09-30 | 17 | USD |
ComprehensiveIncome | 31,661,000 | 2025-09-30 | 28 | USD |
SocialSecurityContributions | 30,138,000 | 2025-09-30 | 26 | USD |
ComprehensiveIncomeAttributableToOwnersOfParent | 30,047,000 | 2025-09-30 | 28 | USD |
ConstructionInProgress | 29,635,000 | 2017-12-31 | 2 | USD |
OtherExpenseByNature | 29,131,000 | 2025-09-30 | 26 | USD |
FuelAndEnergyExpense | 27,549,000 | 2025-09-30 | 26 | USD |
ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax | -26,997,000 | 2024-12-31 | 20 | USD |
IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment | 26,396,000 | 2025-09-30 | 18 | USD |
RawMaterialsAndConsumablesUsed | 26,261,000 | 2025-09-30 | 26 | USD |
IncomeTaxRelatingToChangesInRevaluationSurplusOfOtherComprehensiveIncome | -26,127,000 | 2025-09-30 | 21 | USD |
FinanceIncome | 25,036,000 | 2025-09-30 | 28 | USD |
OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation | -24,867,000 | 2025-09-30 | 28 | USD |
IncreaseDecreaseThroughOtherContributionsByOwners | 24,004,000 | 2025-09-30 | 1 | USD |
OtherComprehensiveIncome | 23,570,000 | 2025-09-30 | 28 | USD |
IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl | 21,964,000 | 2015-12-31 | 1 | USD |
AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment | 21,331,000 | 2022-12-31 | 4 | USD |
DeferredTaxAssets | 20,968,000 | 2025-09-30 | 19 | USD |
UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised | 20,200,000 | 2020-12-31 | 3 | USD |
CurrentPrepaidExpenses | 19,928,000 | 2025-09-30 | 18 | USD |
CurrentDividendPayables | 18,026,000 | 2025-09-30 | 6 | USD |
DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities | 17,500,000 | 2025-09-30 | 11 | USD |
TradeAndOtherCurrentReceivablesDueFromRelatedParties | 16,773,000 | 2025-09-30 | 8 | USD |
DerivativeFinancialAssets | 15,042,000 | 2025-09-30 | 17 | USD |
GainsLossesOnFairValueAdjustmentAttributableToPhysicalChangesBiologicalAssets | 13,738,000 | 2024-12-31 | 16 | USD |
IncreaseDecreaseThroughSharebasedPaymentTransactions | 13,595,000 | 2025-09-30 | 26 | USD |
ProfessionalFeesExpense | 13,487,000 | 2025-09-30 | 26 | USD |
InterestReceivedClassifiedAsInvestingActivities | 12,931,000 | 2025-09-30 | 26 | USD |
AdjustmentsForIncreaseDecreaseInTradeAccountPayable | 12,502,000 | 2025-09-30 | 26 | USD |
Goodwill | 12,412,000 | 2017-12-31 | 2 | USD |
AdjustmentsForUnrealisedForeignExchangeLossesGains | -12,323,000 | 2025-09-30 | 26 | USD |
ForeignExchangeGain | 12,323,000 | 2025-09-30 | 14 | USD |
OtherOperatingIncomeExpense | 12,063,000 | 2025-09-30 | 28 | USD |
InventoryWritedown2011 | 12,000,000 | 2024-09-30 | 2 | USD |
ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets | 11,580,000 | 2025-09-30 | 26 | USD |
ReserveOfSharebasedPayments | 11,291,000 | 2025-09-30 | 19 | USD |
PaymentsToAcquireOrRedeemEntitysShares | 10,210,000 | 2025-09-30 | 26 | USD |
PurchaseOfTreasuryShares | 10,210,000 | 2025-09-30 | 26 | USD |
CurrentTaxLiabilitiesCurrent | 10,117,000 | 2025-09-30 | 18 | USD |
OtherCurrentReceivables | 10,059,000 | 2025-09-30 | 18 | USD |
InterestExpenseOnFinanceLeases | 9,524,000 | 2019-12-31 | 3 | USD |
PaymentsOfFinanceLeaseLiabilitiesClassifiedAsFinancingActivities | 9,524,000 | 2019-12-31 | 1 | USD |
MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease | 9,508,000 | 2019-01-01 | 1 | USD |
LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed | 9,308,000 | 2019-01-01 | 1 | USD |
RevenueFromInterest | 9,238,000 | 2025-09-30 | 26 | USD |
NoncurrentDerivativeFinancialAssets | 9,219,000 | 2025-09-30 | 12 | USD |
MinimumOperatingLeasePayments | 9,200,000 | 2019-12-31 | 9 | USD |
CurrentDepositsFromCustomers | 9,162,000 | 2025-09-30 | 18 | USD |
ReductionOfIssuedCapital | 9,000,000 | 2025-06-06 | 3 | USD |
DecreaseDueToHarvestBiologicalAssets | 8,852,000 | 2017-12-31 | 3 | USD |
NoncurrentValueAddedTaxReceivables | 8,390,000 | 2025-09-30 | 18 | USD |
CurrentValueAddedTaxReceivables | 8,237,000 | 2025-09-30 | 18 | USD |
ProfitLoss | 8,091,000 | 2025-09-30 | 28 | USD |
EnergyExpense | 8,044,000 | 2025-09-30 | 26 | USD |
TreasuryShares | 7,940,000 | 2025-09-30 | 19 | USD |
IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset | -7,784,000 | 2025-09-30 | 18 | USD |
WritedownsReversalsOfInventories | 7,594,000 | 2025-09-30 | 26 | USD |
ProfitLossAttributableToOwnersOfParent | 7,037,000 | 2025-09-30 | 28 | USD |
IncreaseDecreaseThroughNetExchangeDifferencesBiologicalAssets | -6,947,000 | 2025-09-30 | 18 | USD |
CurrentNotesAndDebenturesIssuedAndCurrentPortionOfNoncurrentNotesAndDebenturesIssued | 6,751,000 | 2025-09-30 | 18 | USD |
TaxEffectOfRevenuesExemptFromTaxation2011 | 6,746,000 | 2025-09-30 | 26 | USD |
AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities | 6,697,000 | 2025-09-30 | 26 | USD |
DeferredTaxExpenseIncome | -6,186,000 | 2025-09-30 | 26 | USD |
ProfitLossBeforeTax | 6,089,000 | 2025-09-30 | 28 | USD |
GainsLossesOnNetMonetaryPosition | -6,029,000 | 2025-09-30 | 25 | USD |
CurrentDerivativeFinancialAssets | 5,823,000 | 2025-09-30 | 19 | USD |
FinancialLiabilitiesAtFairValue | 5,779,000 | 2024-12-31 | 16 | USD |
UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised | 5,300,000 | 2020-12-31 | 4 | USD |
DerivativeFinancialLiabilities | 5,077,000 | 2025-09-30 | 17 | USD |
FinancialLiabilities | 5,077,000 | 2025-09-30 | 1 | USD |
CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax | 4,891,000 | 2025-09-30 | 18 | USD |
AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives | 4,598,000 | 2025-09-30 | 26 | USD |
CurrentTaxExpenseIncome | 4,184,000 | 2025-09-30 | 26 | USD |
TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense | 4,132,000 | 2025-09-30 | 5 | USD |
OtherFinanceCost | 3,936,000 | 2025-09-30 | 26 | USD |
CurrentDerivativeFinancialLiabilities | 3,871,000 | 2025-09-30 | 19 | USD |
OtherProvisions | 3,752,000 | 2024-12-31 | 24 | USD |
AdjustmentsForFairValueGainsLosses | -3,614,000 | 2025-09-30 | 26 | USD |
GainLossRecognisedOnMeasurementToFairValueLessCostsToSellOrOnDisposalOfAssetsOrDisposalGroupsConstitutingDiscontinuedOperation | 3,614,000 | 2025-09-30 | 26 | USD |
TransferFromToInventoriesAndOwnerOccupiedPropertyInvestmentProperty | 3,614,000 | 2025-09-30 | 18 | USD |
DisposalsPropertyPlantAndEquipment | 3,609,000 | 2025-09-30 | 18 | USD |
AdditionsFromPurchasesBiologicalAssets | 3,469,000 | 2025-09-30 | 18 | USD |
OtherNoncurrentNonfinancialAssets | 3,426,000 | 2025-09-30 | 19 | USD |
ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities | 3,292,000 | 2025-09-30 | 26 | USD |
BorrowingCostsCapitalised | 3,112,000 | 2025-09-30 | 18 | USD |
GainsLossesOnChangeInFairValueOfDerivatives | 3,091,000 | 2025-09-30 | 17 | USD |
OtherCurrentPayables | 3,042,000 | 2025-09-30 | 18 | USD |
IncreaseDecreaseThroughNetExchangeDifferencesInvestmentProperty | -2,948,000 | 2025-09-30 | 18 | USD |
IncomeTaxesPaidRefundClassifiedAsOperatingActivities | 2,852,000 | 2025-09-30 | 26 | USD |
GainsLossesOnDisposalsOfInvestmentProperties | 2,756,000 | 2025-09-30 | 26 | USD |
OtherLongtermProvisions | 2,668,000 | 2025-09-30 | 19 | USD |
IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome | -2,526,000 | 2021-12-31 | 10 | USD |
AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill | 2,123,000 | 2017-12-31 | 2 | USD |
AdjustmentsForIncomeTaxExpense | -2,002,000 | 2025-09-30 | 26 | USD |
IncomeTaxExpenseContinuingOperations | -2,002,000 | 2025-09-30 | 28 | USD |
AdditionalProvisionsOtherProvisions | 2,001,000 | 2024-12-31 | 16 | USD |
ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment | 2,000,000 | 2024-09-30 | 2 | USD |
ProvisionUsedOtherProvisions | 1,979,000 | 2024-12-31 | 16 | USD |
OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome | -1,939,000 | 2025-09-30 | 26 | USD |
RevenueFromGovernmentGrants | 1,900,000 | 2025-09-30 | 2 | USD |
OtherNoncurrentReceivables | 1,892,000 | 2025-09-30 | 18 | USD |
NumberOfShareOptionsExercisableInSharebasedPaymentArrangement | 1,762,000 | 2019-12-31 | 9 | shares |
CostOfPurchasedEnergySold | 1,684,000 | 2025-09-30 | 26 | USD |
AdditionsOtherThanThroughBusinessCombinationsBiologicalAssets | 1,676,000 | 2022-12-31 | 2 | USD |
GainsLossesOnFairValueAdjustmentInvestmentProperty | 1,623,000 | 2025-09-30 | 23 | USD |
ComprehensiveIncomeAttributableToNoncontrollingInterests | 1,614,000 | 2025-09-30 | 28 | USD |
AdjustmentsForAmortisationExpense | 1,480,000 | 2025-09-30 | 26 | USD |
IncreaseDecreaseThroughTransfersFromToInvestmentPropertyPropertyPlantAndEquipment | 1,380,000 | 2021-12-31 | 10 | USD |
ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities | 1,316,000 | 2025-09-30 | 26 | USD |
LeaseAndSubleasePaymentsRecognisedAsExpense | 1,288,000 | 2019-12-31 | 9 | USD |
IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill | -1,247,000 | 2017-12-31 | 2 | USD |
TradingIncomeExpenseOnDerivativeFinancialInstruments | 1,246,000 | 2024-12-31 | 16 | USD |
PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities | 1,244,000 | 2025-09-30 | 26 | USD |
NoncurrentDerivativeFinancialLiabilities | 1,206,000 | 2025-09-30 | 13 | USD |
TaxEffectOfForeignTaxRates | 1,104,000 | 2025-09-30 | 26 | USD |
ProfitLossAttributableToNoncontrollingInterests | 1,054,000 | 2025-09-30 | 28 | USD |
OtherFinanceIncome | 1,016,000 | 2025-09-30 | 26 | USD |
NoncurrentPayables | 990,000 | 2025-09-30 | 19 | USD |
AmortisationIntangibleAssetsOtherThanGoodwill | -936,000 | 2017-12-31 | 2 | USD |
OtherShorttermProvisions | 767,000 | 2025-09-30 | 19 | USD |
OtherNoncurrentPayables | 728,000 | 2025-09-30 | 18 | USD |
TradeAndOtherCurrentPayablesToRelatedParties | 682,000 | 2025-09-30 | 6 | USD |
DividendsRecognisedAsDistributionsToNoncontrollingInterests | 629,000 | 2024-12-31 | 6 | USD |
GainsLossesOnCashFlowHedgesBeforeTax | 601,000 | 2024-12-31 | 19 | USD |
FinanceLeaseLiabilities | 595,000 | 2019-01-01 | 6 | USD |
ContingentRentsRecognisedAsIncomeClassifiedAsOperatingLease | 564,000 | 2019-12-31 | 9 | USD |
NoncurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax | 560,000 | 2025-09-30 | 18 | USD |
GainsLossesOnFairValueAdjustmentAttributableToPriceChangesBiologicalAssets | 525,000 | 2024-12-31 | 16 | USD |
MinimumFinanceLeasePaymentsPayable | 522,000 | 2019-12-31 | 6 | USD |
TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss | 358,000 | 2025-09-30 | 26 | USD |
AcquisitionsThroughBusinessCombinationsOtherProvisions | 300,000 | 2022-12-31 | 2 | USD |
AdjustmentsForDecreaseIncreaseInOtherAssets | 262,000 | 2025-09-30 | 26 | USD |
NoncurrentPayablesToTradeSuppliers | 262,000 | 2025-09-30 | 8 | USD |
AdjustmentsForProvisions | -171,000 | 2025-09-30 | 26 | USD |
EffectOfExchangeRateChangesOnCashAndCashEquivalents | -148,000 | 2025-09-30 | 26 | USD |
PurchaseOfBiologicalAssets | 138,000 | 2025-09-30 | 26 | USD |
IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions | 131,000 | 2024-12-31 | 16 | USD |
AdjustmentsForIncreaseDecreaseInOtherOperatingPayables | -85,000 | 2025-09-30 | 26 | USD |
IncreaseDecreaseThroughExerciseOfOptions | 45,000 | 2025-09-30 | 14 | USD |
ProceedsFromExerciseOfOptions | 45,000 | 2025-09-30 | 11 | USD |
NumberOfEmployees | 7,790 | 2017-12-31 | 3 | employee |
ClosingForeignExchangeRate | 177 | 2022-12-31 | 1 | ARS |
WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted | 8 | 2021-05-13 | 30 | USD |
ParValuePerShare | 2 | 2024-12-31 | 8 | USD/shares |
DividendsRecognisedAsDistributionsToOwnersPerShare | 0 | 2024-11-27 | 12 | USD/shares |
DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse | 0 | 2024-12-31 | 1 | pure |
WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16 | 0 | 2019-01-01 | 1 | pure |
BasicEarningsLossPerShare | 0 | 2025-09-30 | 28 | USD/shares |
DilutedEarningsLossPerShare | 0 | 2025-09-30 | 28 | USD/shares |
DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections | 0 | 2024-12-31 | 1 | pure |
AdjustmentsForGainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociates | 0 | 2022-12-31 | 9 | USD |
AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod | 0 | 2017-12-31 | 3 | USD |
BorrowingCostsRecognisedAsExpense | 0 | 2023-12-31 | 18 | USD |
CashAdvancesAndLoansMadeToOtherPartiesClassifiedAsInvestingActivities | 0 | 2017-12-31 | 3 | USD |
CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013 | 0 | 2025-09-30 | 20 | USD |
CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities | 0 | 2024-12-31 | 18 | USD |
DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities | 0 | 2025-09-30 | 26 | USD |
GainLossOnHedgeIneffectivenessRecognisedInOtherComprehensiveIncome | 0 | 2025-09-30 | 20 | USD |
GainsLossesOnDisposalsOfInvestments | 0 | 2022-12-31 | 9 | USD |
GainsLossesOnLitigationSettlements | 0 | 2018-12-31 | 6 | USD |
ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill | 0 | 2018-12-31 | 6 | USD |
IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome | 0 | 2025-09-30 | 26 | USD |
IncreaseDecreaseThroughAppropriationOfRetainedEarnings | 0 | 2024-12-31 | 8 | USD |
IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment | 0 | 2025-09-30 | 18 | USD |
NoncurrentTradeReceivables | 0 | 2018-12-31 | 4 | USD |
OtherComprehensiveIncomeNetOfTaxCashFlowHedges | 0 | 2025-09-30 | 28 | USD |
OtherCurrentNonfinancialAssets | 0 | 2022-12-31 | 13 | USD |
OtherInventories | 0 | 2020-12-31 | 8 | USD |
ProceedsFromChangesInOwnershipInterestsInSubsidiaries | 0 | 2017-12-31 | 3 | USD |
ProceedsFromIssueOfBondsNotesAndDebentures | 0 | 2019-12-31 | 9 | USD |
ProceedsFromIssuingShares | 0 | 2019-12-31 | 9 | USD |
ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax | 0 | 2025-09-30 | 20 | USD |
ReserveOfCashFlowHedges | 0 | 2024-12-31 | 17 | USD |
ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod | 0 | 2017-12-31 | 3 | USD |
TaxEffectFromChangeInTaxRate | 0 | 2024-12-31 | 24 | USD |
TaxEffectOfTaxLosses | 0 | 2019-12-31 | 9 | USD |
ForeignExchangeLoss | 0 | 2025-09-30 | 11 | USD |
GainRecognisedInBargainPurchaseTransaction | 0 | 2024-12-31 | 9 | USD |
IncreaseDecreaseThroughTreasuryShareTransactions | 0 | 2025-09-30 | 4 | USD |
IncreaseDecreaseThroughTransferBetweenRevaluationReserveAndRetainedEarnings | 0 | 2024-12-31 | 3 | USD |
What to be careful about
What this model itself distrusts about AGRO's figures. Written by the derivation as it ran, not added afterwards.
- revenue is annual, not TTM
- operating income is annual, not TTM
- revenue period ends 2024-12-31 (653 days ago) - the tag chain found nothing recent, so treat this row as unscored
- forward EPS growth +29.1% is analyst consensus, not a filing: consensus 2027 EPS 1.39 against trailing 0.65, over 3 year(s), from 3 analysts (taken 2026-10-11)
- durability rests on 3 of 4 inputs; not tagged: contracted coverage